Out-licensing

A Novel Synthesis of 2'-Deoxy-2'-[18F]fluoro-9-ß-D-arabino-furanosylguanine ([18F]F-AraG): Imaging T Cell Activation with PET

Stanford researchers have developed a novel PET agent for diseases stemming from T cell origin. The probes help visualize the disease status as well as the progress of therapy. 2-Deoxy-9-ß-D-arabino-furanosylguanine (AraG) is a guanosine analogue with proven efficacy in the treatment of T cell lymphoblastic disease, such as leukaemia. The derivative 2-deoxy-2-fluoro-9-ß-D-arabino-furanosylguanine (F-AraG) is known to exhibit selective T-cell toxicity. It is metabolised in a unique fashion by deoxyguanosine kinase and incorporated into mitochondrial DNA. The researchers have developed a novel way to synthesize [18F]F-AraG which can be used as a new PET imaging agent for the specific detection of disease of T cell origin. The synthesis method developed here can be used with other PET probes.

Conclusion

A novel Pet agent has been synthesised for use in the imaging of T cell activation.

Relevance/Opportunity

Please enquire regarding licensing or codevelopment partnerships quoting reference no. S09-209.

Registered